Domestic availability and price of rubicatin/rubicatin

Lurbinectedin/Lurbinectedin is a new anti-tumor drug mainly used to treat malignant tumors such as small cell lung cancer (SCLC). The drug's mechanism of action is to interfere with the proliferation and growth of cancer cells by binding to DNA and inhibiting the transcription process. The clinical application of rubicatin is mainly focused on patients with small cell lung cancer who are resistant to or relapsed with platinum-based chemotherapy, and has shown certain efficacy and safety.

Currently, rubicatin has not been approved for marketing in China, so domestic patients are not yet able to obtain the drug through formal channels. Despite this, its original drug has been sold in the international market, especially in Europe and the United States, and has gained certain clinical recognition. According to relevant information, the original drug of Rubicatin sold in Hong Kong, Specification 4mg, may be sold for more than 20,000 yuan per vial, and the specific price will be affected by exchange rate fluctuations. In addition, there are multiple versions of Rubicon on the overseas market, and their prices vary greatly. For example, the US version is priced at more than 90,000 yuan, while the Singapore version also costs more than 30,000 yuan.

Rubicatin was developed primarily in response to the current shortage of drugs for the treatment of small cell lung cancer, providing a new treatment option, especially when some chemotherapy regimens are ineffective. Although its clinical trial results show good effectiveness, many patients are unable to get this potential treatment opportunity because it has not yet been launched in the country, which to a certain extent limits its development in the Chinese market.

The clinical research of Rubicatin is still ongoing, and it is expected to be launched in the Chinese market if more clinical data support and regulatory approval are obtained in the future. At the same time, domestic medical insurance policies may also change as the drug is launched, thereby affecting its market price and patient accessibility. At this stage, there are no generic drugs of Rubicatin on the market in China, resulting in relatively limited treatment options for patients.